IncellDx collaborates with Pfizer in a COVID-19 Phase 2 Clinical Trial


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ IncellDx collaborates with Pfizer in a COVID-19 Phase 2 Clinical Trial
IncellDx to study Maraviroc, a CCR5 antagonist, in a COVID-19 phase 2 clinical trial

IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer's FDA-approved CCR5 antagonist Maraviroc. The trial "Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2" seeks to establish whether a one week treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.

Maraviroc, an oral medication, will be administered for seven days. Blood will be collected at Day 0, 3, 7 and 14. IncellDx is performing a Maraviroc-specific CCR5 Receptor Occupancy assay, their IncellKINE RUO Cytokine Storm quantification panel, immune profiling with T-cell exhaustion and macrophage polarization as well as SARS-CoV-2 plasma viral load (pVL) .

Bruce Patterson MD, CEO of IncellDx commented that "Since the beginning of the COVID-19 pandemic, IncellDx has led the way in defining the role of CCR5 antagonism in diagnosis and treatment of COVID-19. We are excited to collaborate in the study of Maraviroc's potential as a therapeutic for COVID-19. In our studies, we have shown that CCR5 antagonism can restore immune homeostasis, quiet the cytokine storm, and reduce plasma viral load of SARS-CoV-2 RNA."

IncellDx, Inc., located in San Carlos, California, is a single-cell, molecular diagnostics company dedicated to revolutionizing healthcare, one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, the company's focus is on critical life threatening diseases in the areas of COVID-19, infectious disease and oncology/immuno-oncology, i.e. cervical, head and neck, lung, bladder, breast and prostate cancers.

Tags : #IncellDx #Pfizer #LatestNewsonIncellDx20thOct #SARS-CoV-2 #BrucePatterson #LatestPharmaNews20thOct

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026